KMTS Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $22.6 million, a 53% increase year-over-year.
Gross Margin: 50.6%, marking the first time it surpassed 50%, up 11 points from the previous year.
Operating Expenses: $43.2 million, including $1 million in non-recurring costs; adjusted operating expenses were $33.5 million.
Net Loss: GAAP net loss of $32.8 million, compared to $20.6 million in the prior year.
Adjusted EBITDA Loss: $19.7 million, up from $16.1 million year-over-year.
Cash Position: $175.4 million in cash and equivalents, not including $148 million from a recent equity offering.

2. Strategic Updates and Business Highlights

Prescription Growth: Approximately 4,700 prescriptions for the Assure system were written, reflecting a 54% year-over-year increase.
Market Penetration: The wearable cardioverter defibrillator (WCD) market remains underutilized, with only 14% of eligible patients currently receiving therapy.
Clinical Evidence: Presentation of ACE PAS study results at the American Heart Association meeting demonstrated the Assure system's effectiveness, potentially influencing clinical guidelines.
Sales Expansion: Increased sales territories from 80 to approximately 100, with ongoing hiring of clinical specialists to enhance account management.
Revenue Cycle Management: Improved in-network patient fittings from 70% to the low 80s, enhancing revenue metrics.

3. Forward Guidance and Outlook

Fiscal Year 2026 Revenue Guidance: Increased to $91 million, representing a 52% growth compared to FY 2025, up from previous guidance of $88 million.
Gross Margin Expectations: Continued expansion anticipated, with a target of achieving 70% plus gross margins in the coming years.

4. Bad News, Challenges, or Points of Concern

Net Loss: The company reported a significant net loss, which may raise concerns among investors regarding profitability.
Operating Expenses: Increased expenses due to investments in commercial expansion and public company costs, which could pressure margins if not managed effectively.
Market Competition: While KMTS is gaining market share, competitors are also growing, indicating a competitive landscape that may limit market capture.
Guideline Changes: While the company believes clinical evidence supports a review of existing guidelines, there is no guaranteed timeline for updates, which could impact market growth.

5. Notable Q&A Insights

Market Growth: Management confirmed low double-digit growth in the WCD market, with anecdotal evidence of increased clinician awareness and prescribing behavior following the ACE PAS study.
Sales Force Productivity: The company is on track to double its sales force, with plans to continue hiring to support growth.
Guideline Influence: Management emphasized that while guideline changes could enhance market penetration, the company's growth strategy does not rely on them.
Prescription Volume Sustainability: Management expressed confidence in maintaining strong prescription growth, attributing it to effective competition and account management strategies.
Investment Use: Proceeds from the recent equity offering will be strategically used to support growth initiatives and enhance the company’s balance sheet.

Overall, KMTS reported strong financial performance in Q2 2026, driven by significant revenue growth and gross margin expansion, while also outlining strategic initiatives to further penetrate the WCD market. However, challenges remain, particularly regarding profitability and competitive pressures.

KMTS — KESTRA MEDICAL TECHNOLOGIES, LTD.